Stabilised Hyaluronic Acid (sHA) gel as a novel marker for breast cancer tumour bed cavity: Surgical feasibility
Loading...
Citations
Scopus:
Altmetric:
Altmetric::
Download
Associated Records
File Licence
Editors
Date
2024-03-01
Source Title
Clinical and Translational Radiation Oncology
Journal Title
Journal ISSN
Volume Title
Publisher
ELSEVIER IRELAND LTD
Melbourne Authors
Affiliation
Surgery (Austin & Northern Health)
Document Type
Journal Article
Subject Code
Citation
Yeh, J., Chew, G., Ng, S. L., Ooi, W. M., Loh, S. W., Hyett, A., Leech, T., Bevington, E., Huynh, J., Sim, J., Foroudi, F., Ng, S. P. & Chao, M. (2024). Stabilised Hyaluronic Acid (sHA) gel as a novel marker for breast cancer tumour bed cavity: Surgical feasibility. Clinical and Translational Radiation Oncology, 45, https://doi.org/10.1016/j.ctro.2024.100745.
Access Status
Open Access
Access URL
Open Access URL
published version
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
INTRODUCTION: Consistent delineation of the breast conserving surgery (BCS) tumour bed (TB) for breast cancer remains a challenge for radiation oncologists. Accurate delineation allows for better local control and reduces toxicity when planning partial breast or TB boost radiation therapy (RT). METHODS: In the operating theatre (OT) breast surgeons inserted stabilised hyaluronic acid (sHA) gel as small drops approximately one cm into the walls surrounding the resection cavity. Surgical feasibility was determined by the rate of successful sHA gel insertion procedure, the ease of insertion as rated by surgeons, the time required for insertion procedure, the quantity used, and any adverse events (AE) relating to sHA gel insertion. RESULTS: Thirty-five patients were enrolled. All patients underwent sHA gel insertion successfully. The procedure added a median of 2.8 min to the OT time and was rated as 'easy' in 89 % of patients. There were no immediate AE in OT. Five (14 %) patients experienced a grade 2 or higher AE. Three of the five patients were prescribed oral antibiotics for breast infection. Two of the five patients experienced a grade 3 AE - haematoma which required evacuation in OT day 1 post-BCS, and infected seroma which required drainage and washout in OT 2 months post-BCS. All five patients recovered and underwent the planned adjuvant therapies for their BC. The AE data reflects common risks with standard BCS and are not clearly attributed to sHA gel insertion alone. CONCLUSION: We show that sHA gel is surgically feasible as a marker to help define the TB cavity for post-BCS adjuvant MRI-based RT planning.